Research programme: cancer therapy - Immusol/Novartis

Drug Profile

Research programme: cancer therapy - Immusol/Novartis

Alternative Names: Cancer therapy research programme - Immusol/Novartis

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Immusol; Novartis
  • Developer iTherX Pharmaceuticals; Novartis
  • Class Gene therapies
  • Mechanism of Action Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Aug 2007 This programme is still in active development
  • 10 Oct 2001 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top